Shop By
Catalog No.
Product Name
Application
Product Information
Citations
-
HBV Inhibitor
(-)-Carbovir is a potent inhibitor of Hepatitis B virus (HBV) replication. It exhibits antiviral activity by specifically targeting and interfering with HBV polymerase, thereby disrupting viral nucleic acid synthesis. This compound is primarily used in research contexts focused on developing therapeutic strategies for HBV infections and understanding the mechanisms of viral resistance. -
HBV Inhibitor
Bentysrepinine is an orally active inhibitor of the hepatitis B virus (HBV) that exhibits potent antiviral activity. It demonstrates favorable pharmacokinetic properties, with notable bioavailability across different species, including rats, dogs, and monkeys, and shows no accumulation in monkeys after 90 days of administration. This compound is being investigated for its potential applications in antiviral therapies and hepatitis research. -
HBV Inhibitor
HBV-IN-6 is a potent inhibitor of Hepatitis B Virus (HBV) with an EC50 value of 44 nM. This compound effectively interferes with viral replication, making it a valuable tool for research focused on HBV-related mechanisms and therapeutic strategies. Its efficacy underscores its potential application in developing effective treatments for HBV infections. -
HBV Inhibitor
Antiviral Agent 38 is a potent inhibitor of the hepatitis B virus (HBV). This compound demonstrates significant antiviral activity, making it a valuable tool for research on HBV infections and their associated pathologies. Its efficacy positions it as an important reagent for studying HBV biology and potential therapeutic interventions. -
HBV DNA Inhibitor
HBV-IN-38 is an HBV DNA inhibitor, exhibiting an effective concentration (EC50) of ≤100 nM. This compound is primarily utilized in research to investigate the mechanisms of hepatitis B virus (HBV) infections and to evaluate potential therapeutic interventions against HBV replication. -
HBV Inhibitor
Rolicyprine is a potent inhibitor of Hepatitis B Virus (HBV) that also exhibits neuroprotective activity. It has been shown to alleviate depressive symptoms and promote neuroregeneration, making it relevant for neuropsychiatric research. Additionally, Rolicyprine demonstrates potential in alleviating anxiety, indicating its applicability in studies related to mood disorders and HBV infections. -
HBV Inhibitor
Erythrocentaurin is a natural compound that acts as an inhibitor of the hepatitis B virus (HBV). It exhibits potent antiviral activity, making it a promising candidate for research focused on HBV treatment and management. This compound can be utilized in studies aimed at understanding the mechanisms of HBV replication and the development of novel therapeutic strategies. -
HIV/HBV Inhibitor
L-Fd4A is an adenine derivative that inhibits both human immunodeficiency virus (HIV) and hepatitis B virus (HBV) with effective concentrations (EC50) of 1.5 μM and 1.7 μM, respectively. This compound demonstrates promising antiviral activity while exhibiting low cytotoxicity, making it suitable for research applications in studying HIV and HBV inhibition mechanisms. -
HBV Inhibitor
HBV-IN-37 is a selective inhibitor of Hepatitis B virus (HBV) with an EC50 value of 10 μM. This compound demonstrates significant antiviral activity, making it a valuable tool for researching therapeutic strategies against HBV infection. HBV-IN-37 is useful in elucidating the mechanisms of HBV replication and can serve as a lead compound in the development of antiviral agents targeting HBV. -
HBV Inhibitor
Yhhu6669 is a potent inhibitor of Hepatitis B Virus (HBV), targeting HBV DNA replication. It functions by inducing the formation of DNA-free capsids, effectively reducing HBV levels. In preclinical studies using AAV/HBV-infected mouse models, Yhhu6669 demonstrated significant decreases in both HBV DNA and HBcAg. Additionally, it exhibits favorable pharmacokinetic properties, making it a valuable tool for research in HBV therapeutic development. -
HBV Inhibitor
HBV-IN-7 is a potent inhibitor of Hepatitis B Virus (HBV) with an EC50 of 7 nM. This compound effectively interferes with viral replication, making it a valuable tool for researching HBV pathogenesis and therapeutic interventions. Its strong antiviral activity supports applications in the development of treatments for chronic hepatitis B infections. -
HBV Inhibitor
HBV-IN-8 is a potent inhibitor of hepatitis B virus (HBV) with an effective concentration (EC50) of 287.9 nM. This compound offers significant antiviral activity, making it a valuable tool for research applications focused on HBV infection and treatment mechanisms. HBV-IN-8 is suitable for investigations into the efficacy of antiviral agents in the pursuit of therapeutic strategies against HBV-related diseases. -
Reverse Transcriptase Inhibitor
Lamivudine triphosphate is a potent reverse transcriptase inhibitor that serves as a phosphorylated form of the nucleoside analogue Lamivudine. It effectively disrupts the replication of HIV and HBV viruses through chain termination. Additionally, Lamivudine triphosphate inhibits the RNA-dependent RNA polymerase (RdRp) activity of the NS5B subunit in hepatitis C virus, and can be incorporated into nascent RNA by the SARS-CoV-2 RdRp, thereby preventing mutations in the SARS-CoV-2 RNA. This makes it a valuable reagent for research on viral replication mechanisms and antiviral drug development. -
HBV Inhibitor
GS-8873 is an orally active inhibitor targeting hepatitis B virus (HBV) surface antigen (HBsAg) production, exhibiting an EC50 of 4 nM. This compound demonstrates favorable pharmacokinetic properties in rat models and shows metabolic stability in human hepatocytes. While GS-8873 effectively suppresses HBV, it has been associated with neurofunctional deficits in both rats and cynomolgus monkeys, making it a subject of interest for further research into its biological effects and therapeutic potential. -
HBV Inhibitor
(Rac)-AB-423 is a novel inhibitor targeting hepatitis B virus (HBV) with demonstrated antiviral activity. This compound has shown no induction of CYP1A2, CYP3A4, or CYP2B6 enzymes at elevated concentrations, indicating a favorable safety profile. Additionally, (Rac)-AB-423 exhibits advantageous pharmacokinetic characteristics, including high oral bioavailability and systemic exposure. In preclinical studies using a hydrodynamic injection HBV mouse model, (Rac)-AB-423 achieved a viral load reduction exceeding 2 log, highlighting its potential for therapeutic applications in HBV management. -
HBV Inhibitor
HBV-IN-20 is a potent oral active inhibitor of Hepatitis B Virus (HBV), functioning primarily as a type II core protein assembly modulator (CpAM). With an EC50 of 0.46 µM, HBV-IN-20 disrupts the assembly of HBV core particles, thereby impeding viral replication. This compound is particularly valuable for research applications focused on antiviral therapy and understanding HBV biology. -
HBV Inhibitor
AB-161 is an orally active HBV RNA destabilizer and a selective inhibitor of poly(A) polymerase domain-containing proteins 5 and 7 (PAPD5/7), primarily targeting hepatic tissues. This compound is effective in treating Hepatitis B Virus (HBV) infections by significantly reducing the levels of Hepatitis B surface antigen (HBsAg), with an EC50 value of 2.2 nM for HBsAg. AB-161 is a valuable tool for research applications focused on understanding and addressing HBV infection. -
HBV Inhibitor
LP10 is a non-azole inhibitor targeting CYP51, showing potent activity against Hepatitis B Virus (HBV). This compound disrupts viral replication by inhibiting 14α-demethylation, which is critical for cholesterol biosynthesis in the virus. LP10 is useful for studying HBV infection mechanisms and evaluating antiviral strategies. -
Nucleoside Reverse Transcriptase Inhibitor
Metacavir is a potent nucleoside reverse transcriptase inhibitor primarily targeting the hepatitis B virus (HBV). This orally active compound exhibits significant antiviral activity, making it a valuable tool in the research of antiviral therapies and the development of treatments for HBV infections. Its specificity and efficacy in inhibiting reverse transcriptase contribute to its potential application in studying hepatitis B and related disorders. -
HBV Inhibitor
DVR-01 is a hepatitis B virus (HBV) inhibitor that exhibits antiviral activity in AML12HBV10 and HepDES19 cell lines, with EC50 values of 1.7 and 1.6 μM, respectively. This compound also demonstrates efficacy against drug-resistant HBV mutants, exhibiting EC50 values ranging from 2.403 to 3.273 μM. DVR-01 is suitable for research applications focused on HBV infection and associated diseases, contributing to the understanding of viral mechanisms and potential therapeutic interventions. -
HBV Inhibitor
KKJ00626 is a potent inhibitor of Hepatitis B virus (HBV) with an IC50 of 0.12 to 0.23 μM. This compound targets the interaction between HBV core protein and the surface protein PreS region, effectively preventing the maturation and secretion of HBV particles. Its significant antiviral activity makes KKJ00626 a valuable tool for research in HBV therapeutics and virology studies. -
HBV/HDV Inhibitor
HBV/HDV-IN-5 is a potent inhibitor targeting hepatitis B virus (HBV) and hepatitis D virus (HDV). This compound exhibits significant antiviral activity, making it valuable for research focused on viral hepatitis. HBV/HDV-IN-5 is primarily utilized in studies exploring antiviral therapies and the mechanisms underlying HBV and HDV infections. -
HBV Inhibitor
Morphothiadin mesylate is a potent inhibitor of Hepatitis B Virus (HBV) replication, targeting both wild-type and Adefovir-resistant strains. With an IC50 value of 12 nM, it demonstrates significant antiviral activity. This compound is useful for research applications focused on HBV pathogenesis and the development of antiviral therapeutic strategies. -
Parasite Ubiquinol Oxidation Site Inhibitor
ELQ-121 is a potent inhibitor targeting the ubiquinol oxidation site in parasites. It exhibits remarkable antimalarial activity, with an IC50 of 0.05 nM against both chloroquine-sensitive and multidrug-resistant strains of P. falciparum in vitro. Additionally, ELQ-121 demonstrates high efficacy against T. gondii and N. caninum, with IC50 values below 1 nM, and suppresses B. besnoiti tachyzoite proliferation with an IC50 of 0.49 nM, accompanied by mitochondrial disruption. Furthermore, the compound can be formulated as a polyethylene glycol carbonate ester prodrug, showing in vivo efficacy against P. yoelii in mice, making it a valuable tool for antimalarial research. -
Parasite Inhibitor
BRD5018 is a selective antimalarial agent that targets Plasmodium parasites. This compound functions as a click chemistry reagent, featuring an alkyne group that participates in copper-catalyzed azide-alkyne cycloaddition (CuAAc). Its ability to facilitate this reaction expands its utility in chemical biology applications, particularly in the development of novel therapeutic strategies against malaria. -
Parasite Inhibitor
Antimalarial agent 2 is a novel compound that targets Plasmodium parasites, displaying a rapid in vitro killing profile. This reagent demonstrates potent antiparasitic activity, making it a valuable tool for research into malaria treatment and the development of effective antimalarial therapies. Its oral efficacy indicates potential for further exploration in therapeutic applications against malaria. -
Parasite Inhibitor
Carbarsone, or p-ureidobenzenearsonic acid, primarily functions as a parasite inhibitor with notable efficacy as an amebicide. Historically utilized in human and veterinary medicine, it has been incorporated into poultry and swine feed to mitigate conditions such as blackhead in turkeys, often in conjunction with antibiotics. Its relatively low acute toxicity has prompted research into its safety as a food additive, with studies indicating minimal carcinogenic risk under chronic ingestion, similar to other arsanilic acid derivatives. Carbarsone is metabolized to arsanilic acid, which has been investigated in high-dose studies in canine models. -
Parasite Inhibitor
MMV666810 is a potent parasite inhibitor that targets asexual stages of parasites, exhibiting an IC50 of 5.94 nM. Notably, it demonstrates a 3.3-fold selectivity for late-stage gametocytes over earlier stages, with IC50 values of 179 ± 8 nM for late-stage and 603 ± 88 nM for early-stage gametocytes. This compound is valuable for research applications focused on antimalarial drug development and understanding gametocyte biology. -
Parasite Inhibitor
3-ANOT is a metabolite of Dinitolmide, functioning primarily as a parasite inhibitor. It demonstrates significant efficacy against coccidia, making it essential for research into antiparasitic mechanisms. 3-ANOT is applicable in studies focused on the prevention and treatment of parasitic infections in livestock, especially in poultry. -
Parasite Inhibitor
IWY357 is a potent inhibitor of Plasmodium falciparum, specifically targeting the blood stage of the parasite. This compound exhibits significant efficacy in disrupting the life cycle of the parasite, making it a valuable tool for researchers investigating malaria infection mechanisms and developing therapeutic strategies. Its long-acting properties can contribute to the understanding of parasite biology and assist in the design of novel anti-malarial drugs. -
Nematode Growth Inhibitor
5-(4-Methoxyphenyl)oxazole is a nematode growth inhibitor that targets Caenorhabditis elegans, effectively interfering with hatching and growth processes. This compound, derived from fungal culture broth, exhibits potential in studying nematode biology and assessing the efficacy of nematicidal agents. Its application in research provides valuable insights into nematode management and development. -
Parasite Inhibitor
Nopol is a quinoline derivative that acts as a potent inhibitor of the asexual blood stage of Plasmodium falciparum. Its structural variations result in differing biological activities against various Plasmodium strains, with certain derivatives exhibiting submicromolar EC50 values for specific strains. This compound is valuable for research focused on malaria treatment and the development of antimalarial agents. -
Parasite Inhibitor
Phebestin is a compound that exhibits potent antimalarial activity by inhibiting the growth of Plasmodium spp. It demonstrates significant efficacy in both in vitro and in vivo studies. Additionally, Phebestin interacts with key enzymes associated with the Plasmodium life cycle, making it a valuable tool for research in parasitology and the development of novel antimalarial therapies. -
Parasite Inhibitor
M&B 5124 is a potent inhibitor targeting Schistosoma mansoni, a pathogenic trematode responsible for schistosomiasis. This compound demonstrates significant antiparasitic activity in murine models, making it a valuable tool for research into therapeutic strategies against schistosomiasis. Its efficacy positions it as a candidate for further studies aimed at understanding parasitic infections and developing new treatment options. -
FREP1 Inhibitor
P-orlandin is a specific inhibitor of FREP1, a protein that mediates the binding of Plasmodium gametocytes and ookinetes. This fungal metabolite demonstrates potent activity in blocking Plasmodium falciparum infections in mosquito vectors, making it a valuable tool for research in malaria transmission and vector control studies. Its unique mode of action offers insights into potential strategies for disrupting the lifecycle of malaria parasites. -
Parasite Inhibitor
Melarsonyl dipotassium is a potent anthelmintic agent that targets various parasitic organisms. By interfering with metabolic processes in parasites, it exhibits significant inhibitory activity, making it valuable for research in parasitology and drug development. This compound is particularly relevant in studying the mechanisms of anthelmintic resistance and developing novel therapeutic strategies against parasitic infections. -
Parasite Inhibitor
trans-Cinnamic anhydride is a parasite inhibitor with a primary target of Plasmodium falciparum. This compound, isolated from Cinnamomum zeylanicum, demonstrates moderate antimalarial activity. It is utilized in pharmacological studies aimed at developing therapeutic agents against parasitic infections. -
Parasite Inhibitor
Epsiprantel is a potent anti-Echinococcus compound that functions as a parasite inhibitor, effectively inducing the death of protoscolex, larvae, and adult stages of the parasite in vitro. In vivo studies demonstrate its higher efficacy against mature worms compared to larvae, making it a valuable tool for research into Echinococcus infections and potential therapeutic strategies. Epsiprantel is characterized by its safety profile, showing no adverse side effects in tested models. -
Parasite Inhibitor
6-O-Methacrylate is a trilobolide derivative derived from the leaves of Wedelia trilobata, functioning primarily as a parasite inhibitor. It exhibits significant antimalarial activity with an IC50 of 8.9 μg/mL against the Plasmodium falciparum parasite. Additionally, 6-O-Methacrylate demonstrates antiviral properties by inhibiting the tobacco mosaic virus (TMV). This compound is valuable for research in parasitology and virology. -
Parasite Inhibitor
Cyclobendazole is a benzimidazole derivative targeting protozoan parasites. It demonstrates potent in vitro activity against Trichomonas vaginalis and Giardia lamblia, with IC50 values of 1.1 μg/mL and 0.047 μg/mL, respectively. This compound is useful in research applications focused on combating protozoal infections and studying their biological pathways. -
Parasite Inhibitor
Fenbendazole sulfone is a benzimidazole anthelmintic agent that acts as a parasite inhibitor. It is a minor metabolite of fenbendazole, demonstrating significant activity against various helminths. This compound is primarily utilized in research focused on parasitic infections and anthelmintic drug development. -
Parasite Inhibitor
Anti-infective agent 9 is an inhibitor of Plasmodium falciparum, exhibiting an IC50 of 600 nM, which targets metabolic pathways by downregulating pyruvate levels and interfering with the TCA cycle. This compound demonstrates favorable metabolic stability and low toxicity in human liver cells, making it a viable candidate for further research into antimalarial therapies. Additionally, studies suggest that its mechanism of action may involve pathways beyond 1-deoxy-D-xylulose-5-phosphate synthase (DXPS), highlighting its potential as a multifaceted therapeutic agent in combating malaria. -
Parasite Inhibitor
Lettowienolide is a geranylbenzoquinonoid that targets the Plasmodium falciparum malaria parasite. It demonstrates mild in vitro inhibitory activity, with an IC50 of approximately 20 μg/mL. This compound is relevant for research applications focusing on malaria treatment and the exploration of new therapeutic agents against parasitic infections. -
Parasite Inhibitor
Amabiline is a natural compound derived from specific plant sources, exhibiting potent activity as a parasite inhibitor. It demonstrates notable biological effects that make it valuable for research involving parasitic infections. Amabiline’s unique pharmacological properties may also provide insights into potential therapeutic applications, while its safety profile warrants consideration in various experimental contexts. -
Parasite Inhibitor
Antimalarial Agent 3 is a potent parasite inhibitor that exhibits nanomolar antiplasmodial activity, with an IC50 value of 0.035 μM. This compound demonstrates a high selectivity index, indicating minimal toxicity to mammalian cells. Its effectiveness makes it a valuable tool for research focused on developing antimalarial therapies and understanding parasite biology. -
Parasite Inhibitor
LAPTc-IN-1 is a competitive inhibitor of acidic M17 leucinopeptidase (LAPTc), exhibiting a Ki value of 0.27 μM. This compound demonstrates potent antagonistic activity against the parasite Trypanosoma cruzi, making it a valuable tool for research into parasitic infections. Its specificity towards LAPTc positions it as a potential candidate for the development of therapeutic strategies targeting Chagas disease and other related conditions. -
Parasite Inhibitor
Linearolactone is a compound that exhibits potent anti-Giardia activity, primarily targeting Giardia trophozoites. It induces necrotic cell death in these parasites, which can be attributed to its interaction with a predicted target protein. This compound is valuable for research applications focused on parasitic infections and the development of new therapeutic strategies against Giardia. -
Parasite Inhibitor
Anti-parasitic agent 3 is a potent inhibitor targeting resistant parasites, exhibiting significant anti-parasitic activity. This compound is essential for research applications focused on parasitic infections and the development of effective treatments. Its mechanism of action provides valuable insights into overcoming resistance in various parasitic species. -
Parasite Inhibitor
SSJ-183 is a parasite inhibitor with notable antimalarial activity. It functions by modulating both the efficacy and pharmacokinetic properties relevant to antimalarial treatment. Studies have demonstrated its potential in antimalarial research, positioning SSJ-183 as a significant candidate for the development of new combination therapies targeting malaria. -
Parasite Inhibitor
GSK932121 is a selective antimalarial agent that targets the electron transport chain of Plasmodium falciparum by inhibiting cytochrome bc1 (complex III). This compound disrupts the parasite's metabolic processes, demonstrating significant activity against malaria. Due to its efficient five-step synthesis process, GSK932121 can be produced at kilogram scale, making it suitable for extensive clinical research applications.
